|Videos|October 26, 2022
Real-World Data of Cemiplimab in Patients with Advanced cSCC
Author(s)Nikhil Khushalani, MD
Dr Khushalani provides insights into real-world data that was recently discussed at ESMO 2022 assessing the use of cemiplimab in patients with advanced cSCC.
Episodes in this series
Related to this article
The FDA’s CTGTAC voted that the data from the IGNYTE trial are evaluable and clinically meaningful for RP1/nivolumab in advanced cutaneous melanoma.
The Cellular, Tissue, and Gene Therapies Advisory Committee will review Replimune’s twice-rejected BLA for RP1 plus nivolumab in advanced melanoma.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
PRAME-directed therapies represent a novel approach in the treatment of advanced melanoma.
A research team from Huntsman Cancer Institute at the University of Utah showed a pathway-targeted therapy that could be an effective melanoma treatment.
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
FDA Awards Orphan Drug Designation to Enzomenib for ALL
4
Dr Barot on the FDA Approval of Palbociclib/Trastuzumab ± Pertuzumab in HER2+ Breast Cancer
5